ZW191
Ovarian cancer, Endometrial cancer, Non-small cell lung cancer
Phase 1Active (Fast Track Designation)
Key Facts
Indication
Ovarian cancer, Endometrial cancer, Non-small cell lung cancer
Phase
Phase 1
Status
Active (Fast Track Designation)
Company
About Zymeworks
Zymeworks is a clinical-stage biotech company with a mission to turn scientific innovation into meaningful impact for patients with difficult-to-treat diseases. The company has achieved a significant milestone with the first approval of its partnered asset, zanidatamab (Ziihera®), and is advancing a diverse internal pipeline of next-generation ADCs and multispecific antibodies. Its strategy is built on a dual approach: generating future royalty and milestone cash flows from a portfolio of partnered assets while reinvesting in high-value internal R&D to fuel long-term growth and shareholder returns.
View full company profile